16154-61-3

Basic information

• Product Name: 1-Methyl-4-(3-Methyl-4-nitrophenyl)piperazine
• Synonyms: 1-Methyl-4-(3-Methyl-4-nitrophenyl)piperazine
• CAS NO: 16154-61-3
• Molecular Formula: C₁₂H₁₇N₃O₂
• Molecular Weight: 235.28228
• Mol File: 16154-61-3.mol

Chemical Properties

• Melting Point: 69 °C
• Boiling Point: 389.1±42.0 °C(Predicted)
• Appearance: /
• Density: 1.171±0.06 g/cm3(Predicted)
• PKA: 7.42±0.42(Predicted)
• CAS DataBase Reference: 1-Methyl-4-(3-Methyl-4-nitrophenyl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Methyl-4-(3-Methyl-4-nitrophenyl)piperazine(16154-61-3)
• EPA Substance Registry System: 1-Methyl-4-(3-Methyl-4-nitrophenyl)piperazine(16154-61-3)

Safety Data

• Hazardous Substances Data: 16154-61-3(Hazardous Substances Data)

Usage

Piperazine derivative

A chemical compound derived from piperazine, which is a heterocyclic organic compound structurally similar to azepine.

Substituted phenyl ring

A benzene ring (six carbon atoms forming a ring with alternating single and double bonds) with one or more atoms or groups of atoms attached to it, in this case, a nitro group and a methyl group.

Nitro group

A functional group (-NO2) consisting of an oxygen-nitrogen-oxygen structure, which is known to impart various chemical properties and reactivity to the compound.

Methyl group

A functional group (-CH3) consisting of one carbon atom bonded to three hydrogen atoms, contributing to the structure and properties of the compound.

Intermediate or building block

The compound is commonly used as a starting material or a precursor in the synthesis of more complex pharmaceuticals and agrochemicals.

Biological activities

1-Methyl-4-(3-Methyl-4-nitrophenyl)piperazine has been studied for its potential antifungal and antimicrobial properties, which could be useful in the development of new drugs or treatments.

New material development

The compound has been investigated as a potential ingredient in the development of new materials for various applications, showcasing its versatility and importance in the field of chemistry.

Upstream product

• 109-01-3 1-methyl-piperazine 
• 446-33-3 5-Fluoro-2-nitrotoluene 

Downstream Products

• 16154-71-5 2-methyl-4-(4-methylpiperazine-1-yl)aniline 

Relevant articles and documents

INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS

The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring C, X1, X2, L1, R1, R2, R3, R4, R5, R6, R7, m and n are as defined herein, which are useful as MAP4K1 inhibitors, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by MAP4K1.

PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF

Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.

AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF

Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.

Discovery of Potent, Selective Stem Cell Factor Receptor/Platelet Derived Growth Factor Receptor Alpha (c-KIT/PDGFRα) Dual Inhibitor for the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs)

Stem cell factor receptor (c-KIT) and platelet derived growth factor receptor alpha (PDGFRα) kinases play an important role in gastrointestinal stromal tumors (GISTs). Here, we have discovered an c-KIT/PDGFRα dual inhibitor, compound 31, with single-digit nanomolar potency against c-KIT and PDGFRα. Compared to Imatinib (1), 31 showed better antiproliferative efficacy against various TEL-c-KIT/PDGFRα-BaF3 isogenic cells, including three 1-resistant BaF3 cell lines, as well as against GIST-T1 and GIST-882 cell lines. Furthermore, compound 31 showed a good KinomeScan selectivity (468 kinases) (S score (1) = 0.01 at 1 μM concentration), good metabolic stability in liver microsomes, and no hERG inhibitory activity. It was worth noting that 31 inhibited GIST-T1 tumor growth (TGI = 81.5%) and even the BaF3-TEL-cKIT-T670I tumor progression (TGI = 41.9%, 1-resistant GISTs) at a dosage of 100 mg/kg/day without exhibiting apparent toxicity.

(5,6-DIHYDRO)PYRIMIDO[4,5-E]INDOLIZINES

The invention relates to a compound of Formula (I) wherein, R1 and R2 independently are selected from the group consisting of optionally substituted (6-10C)aryl and (1-5C)heteroaryl groups. The compounds can be used in pharmaceutical compositions, in particular in the treatment of cancer.

INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY

Compounds of formula (I) have checkpoint kinase 1 (CHK1 ) inhibitory activity: wherein R1, R2, R5 and R6 are independently selected from hydrogen, hydroxy, methyl, trifluoromethyl, hydroxymethyl, methoxy, triflu